Endonovo Therapeutics Inc. ENDV Archives

ThursdayFeb 13, 2020 10:51 am

QualityStocksNewsBreaks – Endonovo Therapeutics, Inc. (ENDV) Collaborates with a Stanford University Sponsored Orthopedic Shoulder and Knee Study

Endonovo Therapeutics (OTCQB: ENDV) today announced its collaboration with a Stanford University sponsored Orthopedic Shoulder and Knee Study to determine benefits of Endonovo's tPEMF SofPulse(R) on pain, medication levels and physical function post-operatively. According to the update, the study will evaluate 76 patients with Active and Sham Comparator groups, measured by visual analog scale (“VAS”), at 10 days after, and will allow surgeons to determine postoperative efficacy of Endonovo's SofPulse(R) tPEMF portable device. “The study will allow surgeons to determine if PEMF SofPulse(R) therapy is beneficial in reducing patient-reported post-operative pain,” Endonovo CMO, Dr. Nev Zubcevik DO, said in the…

MondayFeb 10, 2020 9:38 am

QualityStocksNewsBreaks – Endonovo Therapeutics, Inc. (ENDV) Collaborates with Major Universities for the Evaluation of SofPulse(R) for Orthopedic Surgeries

Endonovo Therapeutics (OTCQB: ENDV) today announced the evaluation of its SofPulse(R) device at major universities for orthopedic surgeries. Endonovo’s FDA-Cleared SofPulse(R) is a non-invasive device utilized for the reduction of postoperative pain and edema and represents a low-cost drug-free solution for reducing opioid usage, accelerating patient recovery and preventing opioid addiction following surgical procedures. “We are pleased to announce SofPulse(R) is now being evaluated at major medical universities. We believe this is a unique opportunity for SofPulse(R) to be evaluated, and upon completion and approval, be used as a standard of healthcare moving forward,” Endonovo Therapeutics CEO Alan Collier said…

TuesdayFeb 04, 2020 9:54 am

QualityStocksNewsBreaks – Endonovo Therapeutics, Inc. (ENDV) Reduces Debt, Restructures Balance Sheet

Endonovo Therapeutics (OTCQB: ENDV) today announced the reduction of current liabilities and restructuring of the balance sheet through the approved modification of the terms of the Preferred C shares. “Strengthening our balance sheet is a priority we feel is instrumental in our continued and long-term success. This reduction of debt provides us the flexibility to expand our sales and marketing initiatives and to further develop our nationwide reach to hospitals and other medical facilities we have identified as prospective partners without having financial restraints,” Endonovo Therapeutics CEO Alan Collier said in the news release. “Additionally, reducing the debt increases our…

ThursdayJan 30, 2020 10:30 am

QualityStocksNewsBreaks – Endonovo Therapeutics, Inc. (ENDV) Receives SofPulse(R) Orders From Multiple Plastic Surgery Centers

Endonovo Therapeutics (OTCQB: ENDV) today announced that it has secured sales of SofPulse(R), the company’s FDA-Cleared, non-invasive device utilized for the reduction of postoperative pain and edema, to multiple plastic surgery centers. “SofPulse(R) main distribution model is marketing to major hospitals throughout the US and is beginning to be viewed as the standard of care for postoperative pain and edema reduction for numerous inpatient hospital procedures. With the expansion of our customer base and recent orders from numerous plastic surgery centers, SofPulse(R) demonstrates different applications for its use,” Endonovo Therapeutics CEO Alan Collier stated in the news release. “We are…

MondayJan 27, 2020 10:00 am

QualityStocksNewsBreaks – Endonovo Therapeutics, Inc. (ENDV) Announces Initial Sales of SofPulse(R) Units to a Texas-Based VA Hospital

Endonovo Therapeutics (OTCQB: ENDV) today announced initial sales of SofPulse(R) units into a VA hospital in Texas. Endonovo’s FDA-Cleared non-invasive device for reduction of postoperative pain and edema, SofPulse(R) represents a low-cost, drug-free solution to reduce use of opioids following surgical procedures and help prevent addiction. “I am extremely proud of our team and the effort to reach such a major milestone,” Endonovo CEO Alan Collier stated in the news release. “Serving the veterans is an honor and privilege. Although the process was long and to become an approved vendor was a major accomplishment, we believe serving this VA Medical…

ThursdayDec 12, 2019 12:39 pm

QualityStocksNewsBreaks – Endonovo Therapeutics Inc. (ENDV) Announces Plans to Effect Reverse Stock Split

Endonovo Therapeutics (OTCQB: ENDV), a commercial-stage developer of noninvasive Electroceutical(R) therapeutic devices, today announced that the company has determined to effect a 1-for-1,000 reverse stock split of its issued common shares. According to the update, the reverse stock split will take effect, and the company's common stock will begin trading on a split-adjusted basis on the OTCQB under the ticker symbol "ENDVD" upon completion of FINRA review. Upon effective date of the reverse stock split, every 1,000 shares of the company's issued and outstanding common stock will be automatically combined into one issued and outstanding share of common stock without…

FridayNov 22, 2019 11:49 am

Endonovo Therapeutics Inc. (ENDV) Revenues Up 153% in Q3, SofPulse® Already Successfully in Use at Over 30 Medical Facilities Nationwide

Revenues for the nine months ended September 30, 2019 also increased 293% to $161,720 Company is selling SofPulse(R), its noninvasive Electroceutical(R) therapeutic device, in 7 hospitals, 11 surgery centers and 14 other medical facilities The device is currently under evaluation in 112 other healthcare facilities and Endonovo expects to become a premier supplier to hospitals nationwide for post-operative pain management Commercial-stage developer of innovative medical devices Endonovo Therapeutics Inc. (OTCQB: ENDV) reported its financial results for the third quarter of 2019 via a press release issued on November 19, 2019 (http://ibn.fm/OfcoV). According to the announcement, Endonovo’s revenues increased by 153% to $54,039…

WednesdayNov 20, 2019 12:43 pm

Endonovo Therapeutics Inc.’s (ENDV) Electroceutical Device Brings Rapid Pain Relief, Leads to 30-40% Decrease in Post-Surgical Narcotic Prescriptions

Studies have shown a greater than 2.2-fold reduction in narcotic use over the first 48 hours post-op SofPulse (R) use causes 500% increase in new blood vessels, 59% increase in surgical wound recovery, 57% reduction in pain at one-hour post-op, 55% less pain medication and 50% less inflammation Bioelectric medicine is a $17 billion market, projected to exceed $33 billion annually by 2025 Commercial-stage developer of innovative medical devices Endonovo Therapeutics Inc.’s (OTCQB: ENDV) proprietary SofPulse(R) technology is being successfully used by surgeons at New Hanover Regional Medical Center (NHRMC) in North Carolina to reduce the volume of opioid prescriptions…

WednesdayNov 20, 2019 10:08 am

QualityStocksNewsBreaks – Endonovo Therapeutics Inc. (ENDV) Announces Q3 2019 Results

Endonovo Therapeutics (OTCQB: ENDV), a commercial-stage developer of noninvasive Electroceutical(R) therapeutic devices, on Tuesday announced its financial results for the quarter ended September 30, 2019. Among the highlights, Endonovo reported a 153% increase in revenues for the three months ended September 30, 2019 to $54,039 and a 293% increase in revenues for the nine months ended September 30, 2019 to $161,720, as compared to the same periods last year. “Although our third-quarter operating results and our revenues failed to meet previously announced projections, the efforts throughout the quarter and first nine-months of this year have been extremely positive considering the…

TuesdayNov 19, 2019 11:02 am

Endonovo Therapeutics Inc. (ENDV) Offers Bright Spot in Opioid -Addiction Space with New Pain-Management Option

ENDV has developed a viable pain-control solution for those seeking alternatives to highly addictive opioids The company’s flagship product is an FDA-cleared, easy-to-place, noninvasive device that delivers pulsed electromagnetic frequencies to targeted area In one study, patients treated with Endonovo technology reported a decrease in pain medication by nearly threefold Amid mounting concern about the alarming opioid-addiction crisis, Endonovo Therapeutics Inc. (OTCQB: ENDV) offers one of the few bright spots on the horizon. Endonovo is the commercial-stage developer of noninvasive Electroceutical(TM) Therapeutic devices designed to target patient pain and inflammation, a viable pain-control solution for those desperately seeking options other than highly…

Site Search

Company Search

Tag: Endonovo Therapeutics Inc. ENDV